Skip to main content
. 2021 Jul 25;1:100025. doi: 10.1016/j.lana.2021.100025

Table 2.

Vaccine effectiveness against symptomatic SARS-CoV-2 infection, from the early analysis, with at least one dose and at least 14 days after administration of the first dose, and the two-dose analysis, with effectiveness by dose

Early at-least-one-dose analysis
 Two-dose analysis
OR (95% CI) p-value OR (95% CI) p-value
Unadjusted Analysis
1 dose: 0-13 days after 1st vaccine dose vs. unvaccinated* 1.61 (1.07-2.44) 0.02 1.89 (1.25-2.84) <0.001
1 dose: ≥14 days after 1st vaccine dose vs. unvaccinated* 0.56 (0.32-0.95) 0.03 0.68 (0.38-1.21) 0.19
2 doses: 0-13 days after 2nd vaccine dose vs. unvaccinated* 0.62 (0.30-1.31) 0.22
2 doses: ≥14 days after 2nd vaccine dose vs. unvaccinated* 0.60 (0.25-1.40) 0.23
Adjusted analysis
0-13 days after 1st vaccine dose vs. unvaccinated* 1.66 (1.07-2.57) 0.02 2.07 (1.34-3.21) <0.001
≥14 days after 1st vaccine dose vs. unvaccinated* 0.49 (0.28-0.87) 0.01 0.62 (0.34-1.14) 0.13
2 doses: 0-13 days after 2nd vaccine dose vs. unvaccinated* 0.46 (0.20-1.04) 0.06
2 doses: ≥14 days after 2nd vaccine dose vs. unvaccinated* 0.63 (0.26-1.53) 0.31
Female sex 0.56 (0.38-0.8) <0.001 0.54 (0.37-0.78) <0.001
Self-reported race/skin colour†
Amarela vs. Pardo 0.77 (0.50-1.20) 0.25 0.81 (0.53-1.24) 0.33
Preta vs. Pardo 1.89 (0.41-8.80) 0.41 2.06 (0.44-9.56) 0.36
Branca vs. Pardo 1.18 (0.80-1.75) 0.41 109 (0.74-1.61) 0.66
Occupation category
Administrative vs. Nurse 1.10 (0.74-1.62) 0.65 1.16 (0.79-1.71) 0.45
Clinical vs. Nurse 2.16 (0.82-5.69) 0.12 1.95 (0.76-4.93) 0.16
Other health associated vs. Nurse 0.95 (0.60-1.52) 0.84 0.95 (0.60-1.50) 0.83
Other health professional vs. Nurse 0.89 (0.53-1.51) 0.67 0.92 (0.55-1.56) 0.76
Prior healthcare encounters‡
1-3 vs. 0 1.03 (0.75-1.41) 0.87 1.09 (0.79-1.49) 0.60
≥4 vs. 0 1.50 (0.59-3.87) 0.40 2.92 (1.00-8.52) 0.05
Prior positive SARS-CoV-2 test‡⁎⁎ 0.38 (0.17-0.87) 0.02 0.36 (0.17-0.79) 0.01
⁎

At date of index sample collection for cases and controls

†

Race/skin colour as defined by the Brazilian national census bureau (Instituto Nacional de Geografia e Estatísticas) https://biblioteca.ibge.gov.br/visualizacao/livros/liv63405.pdf

‡

From March, 2020 to the start of the study on 19 January, 2021

⁎⁎

Defined as SARS-CoV-2 RT-PCR or antigen detection